Activin A is a functional component of the anti-endometriotic drug Endoferin

Alexander V Ilyichev, A. V. Ilyichev, Ilyichev AV, Zhanna Yu. Ustenko, Ustenko ZY, Yaroslav A Gushchin, Gushchin YA, A P Bel'kov, Belkov AP, Andrey P Belkov, Liudmila A Belkova, Belkova LA, Kessenikh AG, Andrey G. Kessenikh, Manukhov IV, Ilya V Manukhov, Sergey V. Bazhenov, Bazhenov SV, Alexey V. Vlasov, Vlasov AV, Dmitry G Maldov, Maldov DG, Мальдов Дмитрий Григорьевич, Vladimir N. Uversky, Uversky VN
International journal of biological macromolecules · 2026 · vol. 378 , pp. 153857 · doi:10.1016/j.ijbiomac.2026.153857 · PMID:42537966 · W7172018918
Lab / animal OA: closed public-domain-us
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-11 ⓘ

The anti-endometriotic drug Endoferin's therapeutic efficacy stems from activin A, which suppresses angiogenesis and induces apoptosis in endometriotic lesions, as demonstrated in rat models.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is a prevalent gynecological condition affecting up to 25-40% of women with infertility. Endoferin, a protein complex derived from the bovine ovarian follicles, has demonstrated high efficacy in clinical trials for treating endometriosis. It contains bovine serum albumin and a biologically active protein from the TGF-β superfamily. However, the mechanisms underlying its therapeutic effects are not studied well. Heating Endoferin facilitated the processing of pro-activin A to activin A, resulting in the active drug Endoferin and enhancing its differentiation-inducing activity in Xenopus ectoderm. Inhibitory analysis showed that targeted proteolysis activates Endoferin. Protease -mediated processing of pro-activin A is crucial for activating activin A within the preparation. The morphometric analysis of the endometriomas showed a significant size reduction in rats treated with Endoferin (Cohen's d = 1.5). Immunohistochemical analysis showed that Endoferin treatment significantly decreased VEGF expression (Cohen's d = 1.5) compared to control, as well as reducing the levels of Ki-67 expression (Cohen's d = 1.25), and increased apoptosis indices (Cohen's d = 0,87) in rat endometriotic tissue samples. The therapeutic efficacy of Endoferin in the treatment of endometriosis is explained by the ability of activin A to suppress angiogenesis and induce apoptosis in endometrioid lesions. In addition, Endoferin is isolated from follicular fluid, contains other biologically active substances, and exhibits pronounced antiproliferative activity that cannot be explained solely by the effects of activin A. These findings support the use of Endoferin as a promising treatment option for endometriosis without steroid hormones or their analogues.

My notes (saved in your browser only)

MeSH descriptors

Activins Activins Activins Activins Activins Activins Activins Activins Activins Activins Activins Activins Activins Activins Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (43)

SciLite annotations

organisms 3
xenopus rattus sp. zitter rats
chemicals 1
steroid

Source provenance

europepmc
last seen: 2026-10-19T06:17:24.038039+00:00
openalex
last seen: 2026-10-19T06:08:44.544802+00:00
pubmed
last seen: 2026-10-19T06:10:48.615983+00:00
scilite
last seen: 2026-08-09T09:47:33.675890+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine